

ENDOCRINE ASPECTS OF BREAST CANCER

**Proceedings of a Conference held at the
University of Glasgow, 8th to 10th July
1957**

EDITED BY

ALASTAIR R. CURRIE

B.Sc., M.B., F.R.C.P.Ed.

**Senior Lecturer in Pathology, University of Glasgow ;
Consultant Pathologist, Royal Infirmary, Glasgow**

FOREWORD BY

C. F. W. ILLINGWORTH

C.B.E., M.D., Ch.M., F.R.C.S.Ed., F.R.F.P.S.

**Regius Professor of Surgery, University of Glasgow ;
Consultant Surgeon, Western Infirmary, Glasgow**

This book is protected under the Berne Convention. It may not be reproduced by any means, in whole or in part, without permission. Application with regard to reproduction should be addressed to the Publishers.



E. & S. LIVINGSTONE LTD., January 1958.

EDITOR'S PREFACE

I AM indebted to many colleagues who have contributed to the preparation of the Proceedings of the Conference for publication. The discussion and summaries following the various sections of the book have been written by Professor C. F. W. Illingworth, C.B.E., Professor G. F. Marrian, F.R.S., Dr John A. Loraine and Dr P. R. Peacock. Professor Symington helped in many ways, in particular with the editing of the discussion and in the writing of the summary of the Pathology Section. I am grateful to Professor Illingworth for his advice and encouragement throughout and to Professor Marrian for his guidance on chemical nomenclature.

Dr Ian Carr, Dr J. K. Grant, Dr V. J. O'Donnell, and Dr Beryl Davies read galley proofs and Mr A. P. M. Forrest, Miss Hamilton and Miss A. W. Allan undertook the difficult task of recording the discussions at the time of the Conference. To Miss A. W. Allan I express my most sincere thanks for all the painstaking secretarial work inherent in editing this volume and for her help with the index.

Finally, it is a pleasure to record my appreciation of the cooperation of all contributors and in particular of our publishers. Mr Macmillan and Mr Parker have been very helpful and it is largely due to them that the official report of the Conference is published at this relatively early date.

A. R. CURRIE.

January 1958.

FOREWORD

STUDIES of cancer of the breast have passed through many phases. There was the phase of histopathological inquiries when the microscopic characters were determined and the relation to duct hyperplasia and similar lesions was studied. Then came the phase of clinical investigations into the spread and distribution of metastases and the scope of operative treatment. Then the focus of interest switched to cancer of the breast in the mouse, and during the past few decades this field has yielded a rich harvest, particularly in relation to genetic factors and transmissible agents. Now our attention has been turned to hormonal influences, and once again the human cancer patient occupies the centre of the stage.

At the present time research work on the endocrine aspects of breast cancer is proceeding apace in many different centres throughout the world, at the hands of clinicians—endocrinologists and surgeons—in departments of biochemistry and in special research institutes. It therefore seemed to us that it might be useful to call a conference to review these recent developments, to exchange information on work in progress and to discuss ideas for the future.

The Conference took place, under the auspices of the University of Glasgow, in the Western Infirmary and the Royal Infirmary during the period 8th to 10th July 1957. This volume provides a permanent record of the proceedings. The papers have been printed in the form in which they were presented. For the discussions, in place of a verbatim report we have substituted brief epitomes when necessary, and to each section's debate we have added a critical commentary in order to knit the various discussions together and to present for the reader some idea of the pattern which emerged from our debates.

It is my pleasant duty, on behalf of the Organizing Committee, to thank all those who contributed to the success of the Conference. Through the good offices of the Vice-Chancellor, Sir Hector Hetherington, we were fortunate in obtaining support and a considerable grant of money from a friend of the University who

FOREWORD

prefers to remain anonymous, and we also acknowledge with gratitude the generous help we have received from the Boards of Management of the two teaching hospitals. For all the preparation and the detailed organization we express our particular indebtedness to the two Honorary Secretaries, Dr Alastair Currie and Mr A. P. M. Forrest. In addition, Dr Currie has undertaken the task of editing this volume. This he has done with characteristic zeal, discretion, and assiduity. That the volume is now ready, within six months of the Conference, is in itself a notable tribute to the efficiency with which he and the publishers have addressed themselves to their task.

C. F. W. I.

January 1958.

LIST OF PARTICIPANTS

H. J. B. ATKINS, Guy's Hospital, London.
 F. BIELSCHOWSKY, Dunedin, New Zealand.
 G. BIRKE, Karolinska Sjukhuset, Stockholm.
 D. A. BLAIR, Western Infirmary, Glasgow.
 G. M. BONSER, University of Leeds.
 E. BOYLAND, Chester Beatty Research Institute, London.
 J. B. BROWN, Clinical Endocrinology Research Unit, Edinburgh.
 J. BRUCE, University of Edinburgh.
 R. D. BULBROOK, Imperial Cancer Research Laboratories, London.
 SIR STANFORD CADE, Westminster Hospital, London.
 D. F. CAPPELL, University and Western Infirmary, Glasgow.
 I. A. CARR, Royal Infirmary, Glasgow.
 A. A. CHARTERIS, Western Infirmary, Glasgow. —
 K. COWAN, Department of Health for Scotland, Edinburgh.
 T. CRAWFORD, St George's Hospital, London.
 A. C. CROOKE, Department of Clinical Endocrinology, Birmingham.
 A. R. CURRIE, University and Royal Infirmary, Glasgow.
 J. N. DAVIDSON, University of Glasgow.
 J. B. DEKANSKI, Organon Laboratories, Newhouse, Lanarkshire.
 E. DICZFALUSY, Karolinska Sjukhuset, Stockholm.
 SIR CHARLES DODDS, Courtauld Institute, London.
 N. DOTT, University of Edinburgh.
 M. A. J. T. DOUGLAS, Royal Infirmary, Edinburgh.
 W. P. DUGUID, Royal Infirmary, Glasgow.
 J. D. FERGUSON, Institute of Urology, University of London.
 S. J. FOLLEY, National Institute for Research in Dairying, Reading.
 A. P. M. FORREST, University and Western Infirmary, Glasgow.
 L. FOULDS, Chester Beatty Research Institute, London.
 C. FRANKSSON, Karolinska Sjukhuset, Stockholm.
 J. FURTH, Children's Cancer Research Foundation, Boston.
 T. F. GALLAGHER, Sloan-Kettering Institute, New York.
 W. U. GARDNER, Yale University.
 J. GERBRANDY, Institut Neerlandais du Cancer, Amsterdam.
 HENRIËTTE VAN GILSE, Radio-Therapeutisch Instituut, Rotterdam.
 A. L. GOODALL, University and Royal Infirmary, Glasgow.
 F. C. GREENWOOD, Imperial Cancer Research Laboratories, London.
 G. HADFIELD, Imperial Cancer Research Laboratories, London.
 G. J. HADFIELD, St Bartholomew's Hospital, London.
 R. W. HARRINGTON, Western Infirmary, Glasgow.
 J. L. HAYWARD, Guy's Hospital, London.
 J. HELLSTRÖM, Karolinska Sjukhuset, Stockholm.
 C. L. HEWETT, Organon Laboratories, Newhouse, Lanarkshire.
 R. HOBKIRK, University and Western Infirmary, Glasgow.
 C. F. W. ILLINGWORTH, University and Western Infirmary, Glasgow.
 R. P. JEPSON, University of Sheffield.
 A. G. JESSIMAN, Peter Bent Brigham Hospital, Boston.
 J. M. JOHNSTON, Department of Health for Scotland, Edinburgh.
 J. W. JULL, University of Leeds.
 A. E. KELLIE, Courtauld Institute, London.

LIST OF PARTICIPANTS

- A. KLOPPER, Clinical Endocrinology Research Unit, Edinburgh.
J. A. LORAIN, Clinical Endocrinology Research Unit, Edinburgh.
R. LUFT, Serafimerlasarettet, Stockholm.
MARY MACDONALD, University of Edinburgh.
W. A. MACKEY, University and Royal Infirmary, Glasgow.
R. MCWHIRTER, University and Royal Infirmary, Edinburgh.
K. MAINZER, University of Chicago and Max-Planck-Institut für Biochemie, München.
G. F. MARRIAN, University of Edinburgh.
G. L. MONTGOMERY, University of Edinburgh.
S. R. MORRIS, Western Infirmary, Glasgow.
O. MÜHLBOCK, Institut Neerlandais du Cancer, Amsterdam.
W. MÜLLER, Max-Planck-Institut für Hirnforschung, Cologne.
J. D. N. NABARRO, Middlesex Hospital, London.
E. G. OASTLER, Royal Infirmary, Glasgow.
V. J. O'DONNELL, University and Royal Infirmary, Glasgow.
D. H. PATEY, Middlesex Hospital, London.
P. R. PEACOCK, Royal Beatson Memorial Hospital, Glasgow.
O. H. PEARSON, Sloan-Kettering Institute, New York.
D. A. PEEBLES BROWN, Western Infirmary, Glasgow.
L.-O. PLANTIN, Karolinska Sjukhuset, Stockholm.
F. T. G. PRUNTY, St Thomas's Hospital, London.
B. D. PULLINGER, Royal Beatson Memorial Hospital, Glasgow.
L. N. PYRAH, General Infirmary, Leeds.
B. S. RAY, The New York Infirmary, New York.
W. REID, Royal Infirmary, Glasgow.
W. J. B. RIDDELL, University and Western Infirmary, Glasgow.
J. SLOAN ROBERTSON, Neurosurgical Unit, Glasgow.
A. T. SANDISON, University and Western Infirmary, Glasgow.
R. W. SCARFF, Bland-Sutton Institute for Pathology, Middlesex Hospital, London.
L. A. SCHWEITZER, Chirurgische Universität-Klinik, Heidelberg.
E. F. SCOWEN, St Bartholomew's Hospital, London.
L. SEVERI, University of Perugia, Italy.
H. L. SHEEHAN, University of Liverpool.
A. SLESSOR, University and Stobhill Hospital, Glasgow.
J. A. STRONG, Western General Hospital, Edinburgh.
T. SYMINGTON, University and Royal Infirmary, Glasgow.
A. WESTMAN, Karolinska Sjukhuset, Stockholm.
R. E. WILLIAMS, University and Western Infirmary, Glasgow.
J. STRETTON YOUNG, Imperial Cancer Research Laboratories, London.

ORGANIZING COMMITTEE

C. F. W. ILLINGWORTH (*Chairman*).

D. F. CAPPELL.

A. A. CHARTERIS.

A. R. CURRIE (*Joint Hon. Secretary*).

J. N. DAVIDSON.

A. P. M. FORREST (*Joint Hon. Secretary*).

A. L. GOODALL.

W. A. MACKEY.

P. R. PEACOCK.

J. A. STRONG.

T. SYMINGTON.

CONTENTS

PART ONE

CLINICAL

	PAGE
ADRENALECTOMY IN CANCER OF THE BREAST	2
SIR STANFORD CADE	
ADRENALECTOMY IN CANCER OF THE BREAST	5
J. HELLSTRÖM and C. FRANKSSON	
THE RESULTS OF ADRENALECTOMY WITH GONADECTOMY IN BREAST CANCER	22
L. N. PYRAH	
DISCUSSION AFTER 'ADRENALECTOMY IN BREAST CANCER'	25
HYPOPHYSECTOMY IN THE MANAGEMENT OF METASTATIC CARCINOMA OF THE BREAST	27
ROLF LUFT, HERBERT OLIVECRONA, DENIS IKKOS, LARS BERTIL NILSSON and HARRY MOSSBERG	
SURGICAL HYPOPHYSECTOMY IN THE TREATMENT OF ADVANCED CANCER OF THE BREAST	36
BRONSON S. RAY and OLOF H. PEARSON	
DISCUSSION AFTER 'SURGICAL HYPOPHYSECTOMY IN BREAST CANCER'	45
TREATMENT OF ADVANCED BREAST CANCER BY YTTRIUM-90 IMPLANTATION OF THE PITUITARY	46
A. P. M. FORREST, D. W. BLAIR, S. R. MORRIS, D. A. PEEBLES BROWN, A. T. SANDISON, J. S. VALENTIN and C. F. W. ILLINGWORTH	
PITUITARY ABLATION AND THE VISUAL FIELDS	54
R.-W. HARRINGTON	
RADIOACTIVE GOLD IMPLANTATION OF THE PITUITARY IN THE TREATMENT OF BREAST CANCER	56
K. H. BAUER and L. A. SCHWEITZER	
CHANGES OF PITUITARY FUNCTION FOLLOWING ISOTOPE (³² P) INJECTION AND PITUITARY STALK SECTION	58
P. H. BUXTON, F. L. DAVIES, A. M. JELLIFFE, K. M. JONES, V. LOGUE, J. D. N. NABARRO and G. WALKER	
DISCUSSION AFTER 'OTHER METHODS OF PITUITARY ABLATION'	67
COMPARISONS AND RESULTS OF ADRENALECTOMY AND HYPOPHYSECTOMY	69
H. J. B. ATKINS	

	PAGE
DISCUSSION AFTER 'COMPARISON OF ADRENALECTOMY AND HYPOPHYSECTOMY'	76
TUMOUR AUTONOMY IN CARCINOMA OF THE BREAST: THE PROBLEM OF RECOGNITION OF THE HORMONE- STIMULATED TUMOUR	77
ANDREW G. JESSIMAN	
DISCUSSION AFTER 'TUMOUR AUTONOMY AND THE HORMONE-STIMULATED TUMOUR'	88
PHYSIOLOGICAL EFFECTS OF ADRENALECTOMY AND HYPOPHYSECTOMY	90
OLOF H. PEARSON and BRONSON S. RAY	
METABOLIC EFFECTS OF HYPOPHYSECTOMY AND OF IMPLANTATION OF RADIOACTIVE GOLD AND YTTRIUM IN THE PITUITARY	95
F. T. G. PRUNTY	
REACTIONS FOLLOWING BILATERAL ADRENALECTOMY	98
C. FRANKSSON	
DISCUSSION AFTER 'PHYSIOLOGICAL EFFECTS OF ADRENALECTOMY AND HYPOPHYSECTOMY'	100
CLINICAL—DISCUSSION AND SUMMARY	101
C. F. W. ILLINGWORTH	

PART TWO

PATHOLOGY

ON THE PHARYNGEAL HYPOPHYSIS	106
W. MÜLLER	
HISTOLOGICAL AND CHEMICAL STUDIES ON ADRENAL GLANDS FROM PATIENTS WITH BREAST CARCINOMA	111
T. SYMINGTON, J. GRANT, V. J. O'DONNELL, I. A. CARR and A. P. M. FORREST	
HISTO-HORMONAL STUDIES ON THE HUMAN ANTERIOR HYPOPHYSIS AND THE IMMUNOCHEMISTRY OF ITS HORMONES	122
A. R. CURRIE, B. CRUICKSHANK, C. L. HEWETT and J. B. DEKANSKI	
A POSTMORTEM SURVEY OF THE ADULT BREAST WITH SOME OBSERVATIONS ON GONAD AND PITUITARY	128
A. T. SANDISON	
ALTERATIONS IN THE MICROANATOMY OF THE BREAST AS A RESULT OF CHANGES IN THE HORMONAL ENVIRONMENT	133
J. L. HAYWARD and A. G. PARKS	
PATHOLOGY—DISCUSSION AND SUMMARY	135
T. SYMINGTON and A. R. CURRIE	

PART THREE

HORMONE STUDIES

CHEMICAL NAMES—TRIVIAL AND PROPER	PAGE 140
THE PLACE OF HORMONE ASSAY IN HUMAN BREAST CANCER	141
J. A. STRONG	

ANTERIOR PITUITARY HORMONES AND MAMMOTROPHINS

THE ESTIMATION OF ANTERIOR PITUITARY HORMONES IN PATIENTS WITH MAMMARY CARCINOMA	158
J. A. LORAINÉ	
THE EFFECT OF IRRADIATION OF THE PITUITARY ON GONADOTROPHIN EXCRETION IN WOMEN WITH ADVANCED MAMMARY CANCER	170
E. BOYLAND, B. GODSMARK, W. P. GREENING, P. RIGBY-JONES, J. J. STEVENSON and in part M. A. M. ABUL-FADL	
URINARY GONADOTROPHINS	173
A. C. CROOKE	
MAMMOTROPHIC POTENCY IN HUMAN URINE	174
GEOFFREY HADFIELD	
OBSERVATIONS ON THE RESPONSE OF MAMMARY GLANDS OF MICE TO PROLACTIN	175
R. E. WILLIAMS	
ANTERIOR PITUITARY HORMONES AND MAMMOTROPHINS —DISCUSSION AND SUMMARY	179
J. A. LORAINÉ	

URINARY OESTROGENS

PARALLEL CHEMICAL AND BIOLOGICAL ASSAYS OF URINARY OESTROGENS AFTER ADRENALECTOMY AND HYPOPHYSECTOMY	181
R. D. BULBROOK, F. C. GREENWOOD and P. C. WILLIAMS	
REMARKS ON THE NATURE OF KOBER CHROMOGENS EXCRETED BY SOME OOPHORECTOMIZED-ADRENAL- ECTOMIZED PATIENTS	186
E. DICZFALUSY, G. BIRKE, C. FRANKSSON, J. HELLSTRÖM, S. HULTBERG, L.-O. PLANTIN and A. WESTMAN	
A COMPARISON OF METHODS FOR THE ANALYSIS OF OESTRONE, OESTRADIOL AND OESTRIOL IN EXTRACTS OF HUMAN URINE	196
T. F. GALLAGHER, S. KRAYCHY, JACK FISHMAN, J. B. BROWN and GUY F. MARRIAN	

	PAGE
URINARY OESTROGEN EXCRETION IN THE STUDY OF MAMMARY CANCER	197
J. B. BROWN	
OESTROGEN EXCRETION AFTER HYPOPHYSECTOMY IN BREAST CANCER	208
E. F. SCOWEN	
ON THE CORRELATION BETWEEN STEROID EXCRETION AND CLINICAL RESPONSE TO OOPHORECTOMY PLUS ADRENALECTOMY IN BREAST CANCER	213
G. BIRKE, E. DICZFALUSY, C. FRANKSSON, J. HELLSTRÖM, S. HULTBERG, L.-O. PLANTIN and A. WESTMAN	
URINARY OESTROGENS—DISCUSSION AND SUMMARY	221
G. F. MARRIAN	

URINARY 17-OXOSTEROIDS

THE EFFECT OF HYPOPHYSECTOMY ON THE URINARY EXCRETION OF 17-OXOSTEROIDS	224
MARJORIE E. HOLLIDAY, A. E. KELLIE and A. P. WADE	
URINARY 17-OXOSTEROID EXCRETION AFTER SURGERY FOR BREAST CANCER	239
R. HOBKIRK	
ON THE EXCRETION PATTERN OF 17-OXOSTEROIDS AND CORTICOSTEROIDS IN BREAST CANCER	244
L.-O. PLANTIN, G. BIRKE, E. DICZFALUSY, C. FRANKSSON J. HELLSTRÖM, S. HULTBERG and A. WESTMAN	
THE EXCRETION OF 17-OXOSTEROIDS IN THE URINE OF PATIENTS WITH GENERALIZED CARCINOMATOSIS SECONDARY TO CARCINOMA OF THE BREAST	253
BETTY J. ALLEN, J. L. HAYWARD and W. H. H. MERIVALE	
URINARY 17-OXOSTEROIDS—DISCUSSION AND SUMMARY	263
G. F. MARRIAN	

PART FOUR

EXPERIMENTAL PATHOLOGY

ENDOCRINE ASPECTS OF MAMMARY GROWTH AND FUNCTION, PARTICULARLY IN RELATION TO PITUITARY HORMONES	266
A. T. COWIE and S. J. FOLLEY	
EXPERIMENTAL OBSERVATIONS ON MAMMOTROPES AND THE MAMMARY GLAND	276
JACOB FURTH and KELLY H. CLIFTON	
ON HORMONE DEPENDENCE IN THE TRANSMISSION OF MAMMARY TUMOUR AGENT FROM MALES	283
L. SEVERI, C. BIANCIFIORI, M. OLIVI and F. SQUARTINI	

CONTENTS

	PAGE
STUDIES ON THE HORMONE DEPENDENCE OF EXPERIMENTAL BREAST TUMOURS IN MICE	291
O. MÜHLBOCK	
HORMONE-DEPENDENT TUMOURS IN MICE	296
B. D. PULLINGER	
HORMONAL PROMOTION AND RESTRAINT OF GROWTH OF EXPERIMENTAL MAMMARY TUMOURS	297
CHARLES HUGGINS and KLAUS MAINZER	
HORMONAL MECHANISMS IN MAMMARY CARCINOGENESIS	305
J. W. JULL	
HORMONE RESPONSIVENESS OF MAMMARY TUMOURS .	318
L. FOULDS	
SPLENIC ENLARGEMENT IN ASSOCIATION WITH MAMMARY TUMOURS IN MICE	321
W. REID	
EXPERIMENTAL PATHOLOGY—DISCUSSION AND SUMMARY	323
P. R. PEACOCK	

REVIEW OF THE CONFERENCE

REVIEW OF THE CONFERENCE	326
C. F. W. ILLINGWORTH	

PART ONE

CLINICAL

ADRENALECTOMY IN CANCER OF THE BREAST

SIR STANFORD CADE

Westminster Hospital, London

IN the past four and a half years 170 patients with disseminated breast cancer, including two males, have been submitted to adrenalectomy and gonadectomy. The cases have been analysed with the object of ascertaining the value of the procedure and the length of survival. Histological evidence is available in each case. Previous treatment consisted in surgery to the primary growth, radiotherapy in patients deemed unsuitable for surgery, and the administration of hormones, either oestrogens or androgens, when dissemination of the disease had occurred. At first the operation was undertaken only in the late stages of the disease, but with increased experience it was offered to patients at earlier stages of dissemination.

In no given case can hormone dependence or independence be predicted with accuracy, but it has been observed that aggravation of the patient's condition locally or generally by androgens or oestrogens seems to indicate hormone dependence, and conversely improvement following administration of prednisone is also a sign of hormone dependence. In the later series of cases, hormones were used mainly as a preliminary to adrenalectomy, and only if hormones were well tolerated and improvement achieved was treatment continued for any length of time. The lack of response to hormones is not an indication that the tumour is hormone-independent.

CLINICAL RESULTS

The effect of adrenalectomy is assessed by subjective and objective improvement. In about 40 % of patients no effect on the disease is obtained; there is no subjective improvement, the lesions do not regress, fresh metastases occur and the course of the disease is unaltered. These patients are hormone-independent, although a few of them improved after subsequent hypophysectomy. In 60 % of patients both subjective and objective improvement follows adrenalectomy. The length of improvement varied from 3 months to nearly 4 years. The degree of improvement varied from regression and disappearance of lesions to a state of quiescence when no increase in size or number of metastases occurred. It was noted that if regression occurred it affected all types of metastases, skeletal and

visceral, as well as the local disease in the breast and local recurrences. This apparent law of 'all or nothing' becomes evident only when a sufficiently large number of cases are observed. The postulate that skeletal metastases are more likely to respond than visceral metastases has not been noted in this series of patients. It has also been observed that neither the age of the patient nor the histological variety of the breast cancer can be correlated with the response to treatment. Both premenopausal and postmenopausal women have responded favourably and failure to respond was also distributed in both these groups. All histological types—scirrhous, medullary and adenocarcinoma—provided both successes and failures, and the statement that only the adenocarcinoma is hormone-dependent has not been substantiated.

In patients whose tumours are hormone-dependent, improvement is immediate, sometimes within a few days of adrenalectomy, and often, when a two-stage operation is done, after the removal of the first adrenal. The degree of improvement has been classified as 'excellent' and 'good.' The group 'excellent' includes the most dramatic clinical improvement with a return to a near normal life of patients previously bedridden, requiring pain-relieving drugs, cachectic and with a short expectation of life. By 'good' is meant a degree of improvement with considerable but not complete relief of symptoms and partial regression of lesions without further development of new detectable metastases.

Subjective improvement

The most important subjective improvement is relief of pain from skeletal metastases. In the 'excellent' group relief is immediate and complete. No pain-relieving drugs are necessary. There follows an improvement in general health, increase in weight (which may be due to cortisone), a sense of well-being, capacity for work and a return to normal life. Although subjective improvement cannot be measured or assessed accurately, it is of great clinical importance and, in fact, is what is valued most by the patient.

Objective improvement

This is easier to record with accuracy. Skeletal metastases undergo obvious and recordable changes: osteolytic lesions recalcify; sclerosing lesions become more localized and sclerosis is increased; pathological fractures unite. The appearance of some lesions is that of callus and in some patients the structure of the bone returns to normal.